Why is Glenmark Pharma falling/rising?

As of 04-Aug, Glenmark Pharmaceuticals Ltd. is currently priced at 2,070.20, reflecting a rise of 2.4 points or 0.12%. The stock has shown a trend reversal, gaining after three consecutive days of decline. It is performing in line with its sector, with a delivery volume that has increased by 39.59% compared to the five-day average, indicating rising investor participation. Over the past week, the stock has decreased by 3.42%, but it has delivered a strong performance over the last month with a return of 13.03%. The company has demonstrated a robust ability to service debt, a positive trend in quarterly results, and a favorable valuation compared to peers, all contributing to its recent price movement. In the broader market context, the Sensex has seen a slight increase of 0.16% over the past week, contrasting with Glenmark's decline during the same period. However, Glenmark has significantly outperformed the benchmark over the longer term, with a year-to-date return of 28.68% compared to the Sensex's 3.69%. This consistent performance, alongside high institutional holdings and strong profit growth, suggests that the stock is well-positioned despite short-term fluctuations. Overall, the stock's recent rise can be attributed to positive fundamentals and investor sentiment, even as it navigates recent volatility.